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Background/aim: The aim of this study was to investigate the efficacy of pregabalin on ischemia-reperfusion injuries.
Materials and methods: Fifty-four patients were randomly assigned into 2 groups. A 150-mg tablet of pregabalin was given the night
before and then 1 h before the operation for patients in Group P (pregabalin group, n = 27). A placebo was given to patients in Group C
(control group, n = 27) at the same times. After combined spinal-epidural anesthesia was performed, venous blood samples were taken
before tourniquet inflation (t1), just before tourniquet deflation (t2), and 20 min after tourniquet deflation (t3) for the analysis of total
antioxidant status (TAS), total oxidant status (TOS), catalase (CAT), and ischemia-modified albumin (IMA).
Results: There was no significant difference in TAS levels between the groups for the t3 period. However, the TAS in Group P was
significantly higher in the t3 period than the t2 period (mean ± SD, 0.46 ± 0.1 vs. 0.38 ± 0.2 mmol of Trolox equivalent/L, respectively; P
< 0.05). The CAT level in the t3 period was significantly higher in Group P than Group C (mean ± SD, 53.04 ± 32.1 vs. 35.46 ± 17.2 µmol/
formaldehyde, respectively; P < 0.05). In the t3 period, the TOS was significantly lower in Group P than Group C (mean ± SD, 11.97 ±
5 vs. 18.29 ± 9.9 pg/mL, respectively; P < 0.05). The TOS in Group P was significantly lower in the t3 period than the t2 period (mean ±
SD, 11.97 ± 5 vs. 18.98 ± 10.7 pg/mL, respectively; P < 0.0001).
Conclusion: Pregabalin has no marked antioxidant activity, but it contributes to the antioxidant defense system of an organism.
Keywords: Pregabalin, antioxidant, muscle, ischemia reperfusion injury, total knee replacement

1. Introduction
Tourniquet application during limb surgery involving
stopping the blood flow (ischemia) and flow restoration
(reperfusion) causes ischemia-reperfusion injury (IRI)
[1]. A shortage of oxygen and nutrient supply during
ischemia leads to cellular damage, which further induces
the generation of reactive oxygen species (ROS); this in turn
results in the modification of macromolecules such as lipids,
proteins, and nucleic acids and in the alteration of functions
of the aforementioned molecules in the oxygen reperfusion
phase, required for cell survival [2,3]. IRI not only triggers
irregularity in the cell signals responsible for ROS generation,
apoptosis, and cell differentiation and proliferation, but
also causes local tissue and distant organ damage owing to
the release of metabolites and active neutrophils [3–5]. In
human models, orthopedic surgery involving tourniquet use
is a good strategy for inducing IRI [6,7].

Pregabalin is a gamma-aminobutyric acid (GABA)
analogue that does not interact with GABA receptors.
It reduces Ca++ influx by binding to the α2δ subunit of
voltage-gated calcium channels and consequently inhibits
the release of neurotransmitters such as glutamate and
noradrenaline [8]. However, the mechanism of the
action of pregabalin is not yet completely understood,
and it is currently indicated for the treatment of diabetic
neuropathy, fibromyalgia, and anxiety. Recently, it
was found to be effective against postoperative pain
[4,9,10]. Additionally, some experimental studies have
demonstrated that pregabalin has neuroprotective,
antiinflammatory, and apoptosis-reducing effects, and it
was effective for improving myelin production, cerebral
ischemia, and reperfusion injury [11–14]. However, no
randomized clinical trials in the literature have reported
the effect of pregabalin on ischemia-reperfusion.
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Therefore, to the best of our knowledge, ours is the first
study investigating this mechanism.
In this study, we aimed to determine whether pregabalin
protects against muscular ischemia-reperfusion in
patients undergoing total knee replacement. The primary
outcome of our study was to compare the measurements
of total antioxidant status (TAS), which is a measure of
the combined activities of all antioxidants, immediately
before tourniquet release (ischemia, t2) and 20 min
after tourniquet release (reperfusion, t3). The secondary
outcome was to compare the measurements of TAS, total
oxidant status (TOS), ischemia-modified albumin (IMA)
level, and catalase (CAT) level before ischemia onset (t1)
and at the t2 and t3 time points.
2. Materials and methods
Our study was conducted at the Başkent University Konya
Application and Research Hospital after obtaining ethical
approval from the Ethics Committee of Başkent University
(KA 16/10). The study was registered in the Clinical
Trials Registry (NCT03482544). ASA I–II patients who
were aged between 18 and 65 years and had undergone
unilateral total knee arthroplasty under combined spinalepidural anesthesia were included in the study, and all the
patients were informed both verbally and in writing about
the details of the study before surgery.
The following patients were excluded from the study:
those with a history of allergy to antiepileptic drugs and
prescribed drugs; an ASA status of at least grade III; severe
liver, kidney (with liver enzyme levels 3 times greater than
normal levels and creatinine level greater than 1.5 mg/
kg), or gastrointestinal diseases; psychiatric disorders;
pregnancy or lactation; long-term opioid or nonsteroidal
antiinflammatory drug use or smoking; diabetes; and
other neuropathic diseases. Patients who did not provide
consent to regional anesthesia and those who refused to
participate were also excluded.
The patients’ ages, body mass index (BMI), sex, and
ASA status were recorded. The patients were randomly
assigned by a computerized process into 2 groups, each of
which included 27 patients. Group P (experimental group)
received pregabalin preoperatively, whereas Group C
(control group) did not. Tablets of 150 mg of oral pregabalin
(Lyrica, Pfizer, Germany) were given to patients in Group
P both the evening before and 1 h before the surgery.
Simultaneously, a placebo drug of the same color and size
was given to participants in Group C. Electrocardiography
(ECG), oxygen saturation (SpO2), and noninvasive blood
pressure measurements were taken for patients in both
groups after they were transferred to the operating room,
and these measurements were recorded throughout the
surgery. A 20-gauge intravenous catheter was inserted at
the back of the hand to administer 0.9% NaCl (6 mL/kg),
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but no anxiolytic agent was administered. The first blood
sample (preischemia, t1) was taken from the contralateral
arm after performing radial arterial catheterization. The
patients were then placed in a sitting position. After the
skin was sterilized using an antiseptic solution, local
anesthesia was administered. A 20-G Tuohy needle was
inserted into the epidural space either through the L3–4
or L4–5 space using the loss of resistance technique, the
subarachnoid space was accessed via the needle-throughneedle technique by employing a 27-G Quincke needle,
and heavy bupivacaine 0.5% (3 mL) was administered.
A catheter was inserted into the epidural space for
postoperative analgesia. After anesthesia administration,
the patients were placed in the supine position. Surgery
was initiated when the pin-prick test confirmed that
the sensorial block had reached an optimal level. The
tourniquet was inflated to a pressure that was 2 times more
than the systolic arterial blood pressure. For conducting
IMA, TAS, TOS, and CAT analyses, blood samples were
processed immediately before tourniquet deflation, after
the completion of surgery (ischemia, t2), and at 20 min
after tourniquet deflation (reperfusion, t3).
All blood samples were centrifuged at 3000 rpm for 10
min as soon as they were delivered to the laboratory. The
serum samples were stored at –80 °C until biochemical
analysis. The serum TOS levels were measured using a
TAS kit (Cayman Chemical Co., Ann Arbor, MI, USA) and
expressed as mmol Trolox equivalent/L. The CAT levels
(µM/formaldehyde) were determined using a catalase
assay kit (Cayman Chemical Co.). The serum TOS and
IMA concentrations were determined using an enzymelinked immunosorbent assay (ELISA) by employing kits
purchased from Sunredbio (Shanghai, China). The serum
TOS and IMA levels were expressed as pg/mL and ng/mL,
respectively.
Mean arterial pressure, SpO2, and hazard ratio
during the perioperative period, as well as side effects of
pregabalin such as confusion, dry mouth, and double or
blurred vision, were recorded during the perioperative and
postoperative periods. Additionally, biochemical analysis
results, operative time, and tourniquet time were recorded.
2.1. Statistical analyses
The TAS value during the reperfusion period (t3) was
considered as the primary outcome of this study. In our
preliminary study, the mean TAS values in Groups C and
P were 0.377 mmol/L and 0.478 mmol/L, respectively,
with a standard deviation (SD) of 0.15. According to the
calculator available at http://powerandsamplesize.com,
we calculated that 26 patients would be required in each
group based on a power of 80% and an alpha error of 0.05.
Therefore, assuming a drop-out rate of 5%, a total sample
size of 54 subjects (27 subjects per group) was planned.
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The analyses were conducted using SAS University
9.4 software. The continuous variables were represented
as means and SDs, whereas the categorical variables
were represented as frequencies and percentages. A chisquare test was used for comparing categorical variables
and a t-test was used for comparing continuous variables.
Mixed-effects models were developed to evaluate the
effects of pregabalin and time on continuous outcomes.
Inter- and intragroup comparisons of least squares mean
values were performed using Tukey–Kramer adjustments
whenever applicable. P < 0.05 was considered to be
statistically significant.
3. Results
The patients eligible for this study were analyzed in
terms of their primary outcomes, and the results were
presented in a Consolidated Standards of Reporting Trials
(CONSORT) flow diagram (Figure 1).
The groups were comparable with respect to age, BMI,
sex, ASA status, operative time, and tourniquet time
(Table).

The TAS level was high in Group P and low in Group
C in the t3 period; however, the difference in this value
between the 2 groups was not statistically significant (P >
0.05). In Group P, the TAS level was higher during the t3
period than during the t2 period, and this difference was
statistically significant (mean ± SD, 0.46 ± 0.1 vs. 0.38 ± 0.2
mmol of Trolox equivalent/L; P < 0.05) (Figure 2).
In the t3 period, the CAT level in Group P was
significantly higher than that in Group C (mean ± SD,
53.04 ± 32.1 vs. 35.46 ± 17.2 µmol/formaldehyde; P < 0.05)
(Figure 3).
In the t1, t2, and t3 periods, there was no statistically
significant difference between the groups in terms of IMA;
however, the group × time interaction was statistically
significant (P < 0.05). In the control group, the IMA value
was higher in the t3 period than that in the t2 period, and
this difference was statistically significant (mean ± SD,
137.21 ± 71.2 vs. 105.50 ± 54.4 ng/mL; P < 0.05) (Figure 4).
Although there was no difference between the
groups in terms of TOS, the group × time interaction
was statistically significant (P < 0.001). In the t3 period,

CONSORT Diagram

Enrollment

Assessed for eligibility
(n=54)
Excluded (n=0)
* Did not meet inclusion criteria
(n=0)
* Declined to participate (n=0)
Randomized (n= 54)

11

Allocated to intervention Control Group
12 (n=27)

15

Allocation

Allocated to intervention Pregabalin Group
(n=27)

Follow-Up

Discontinued intervention (n=0)

Discontinued intervention (n=0)

16

Analysis
Analyzed (n=27)
* Excluded from analysis (n=0)
19

Analyzed (n=27)
* Excluded from analysis (n=0)

Figure 1. CONSORT flow diagram of the present study.
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Table. Demographic characteristic of patients.
Group C (n = 27)

Group P (n = 27)

P

Age, years

43.66 ± 11.1

46.76 ± 10.7

0.284a

BMI, kg m–2
ASA status (I/II)

27 ± 2.3
21/6

27.54 ± 3.6
19/8

0.518a
0.535b

Sex (M/F)

11/16

9/18

0.573b

Duration of surgery, min

121.5 ± 14.9

117.8 ± 14.1

0.350a

Tourniquet time, min

124.4 ± 14.9

120.5 ± 14.4

0.340a

Values are presented as number or mean ± standard deviation. ASA: American Society of
Anesthesiologists. BMI: Body mass index.
a
Independent sample t-test.
b
Chi-square test.

Figure 2. Plasma total antioxidant status (TAS) concentration levels of groups. * P < 0.05 between t3
and t2 periods in Group P.

the TOS in Group P was significantly lower than that in
Group C (mean ± SD, 11.97 ± 5 vs. 18.29 ± 9.9 pg/mL;
P < 0.05). In Group P, the TOS was significantly lower in
the t3 period than that in the t2 and t1 periods (mean ± SD,
11.97 ± 5 vs. 18.98 ± 10.7 pg/mL; P < 0.0001 and 11.97 ± 5
vs. 16.49; P < 0.05). In Group C, the TOS was significantly
higher in the t3 period than that in the t2 period (mean ±
SD, 18.29 ± 9.9 vs. 14.99 ± 6.8 pg/mL; P < 0.05) (Figure 5).
There was no significant difference between the groups
with regard to hazards ratio, SpO2, or mean arterial
pressure during the perioperative period, or in terms of
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side effects of pregabalin such as confusion, dry mouth,
and double or blurred vision during the perioperative and
postoperative periods.
4. Discussion
We hypothesized that pregabalin can play a beneficial role
in reducing the incidence of acute muscular ischemia and
reperfusion injury caused by tourniquet application during
total knee arthroplasty. The primary outcome of this study
was measurement of TAS values after tourniquet release.
However, there were no intergroup differences in TAS.
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Figure 3. Plasma catalase (CAT) concentration levels of groups. * P < 0.05 between groups in the t3 period.

Figure 4. Plasma ischemia-modified albumin (IMA) concentration levels of groups. * P < 0.05 between
t3 and t2 periods in Group C.
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Figure 5. Plasma total oxidant status (TOS) concentration levels of groups. * P < 0.05 between groups in
the t3 period. † P < 0.05 between t3 and t2 periods in the Group P. ‡ P < 0.05 between t3 and t1 periods in
Group P.

Here, we revealed that pregabalin had no antioxidative
effects against acute IRI of skeletal muscles, despite having
an impact on TAS, CAT, and TOS in the early reperfusion
period. Our main results were as follows: 1) the CAT level
decreased in Group C, whereas it remained the same in
Group P; 2) the TOS decreased in Group P, whereas it
increased in Group C; and 3) in Group P, the TAS value
in the reperfusion period was higher than that in the
ischemia period.
Although pregabalin is a GABA analogue, it is a potent
new-generation antiepileptic agent; it exerts an effect
by binding to the α2δ subunit of voltage-gated calcium
channels, which causes a reduction in the Ca++ influx, and
by inhibiting the release of glutamate and noradrenaline
from presynaptic terminals [4,8].
Several previous studies demonstrated that pregabalin
reduced the incidence of anxiolytic, analgesic, acute, and
chronic neuropathic pain and also exerted opioid-sparing
effects [15–17]. Moreover, several experimental studies
reported that pregabalin decreased apoptosis and also
exerted neuroprotective and antiinflammatory effects in
spinal cord injury models [12,13]; furthermore, it reduced
the severity of autoimmune encephalomyelitis [14],
improved myelin repair, and reduced glial activation [11].
When glutamate, a Ca++-dependent excitatory
neurotransmitter, enters a cell, it triggers neuronal
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damage and apoptosis by binding to n-methyl-d-aspartate
(NMDA), which is one of the postsynaptic receptors
[18–20]. Another study demonstrated that an anesthetic
agent exerted protective effects against muscular IRI
by inducing ischemia-reperfusion owing to its NMDA
receptor-blocking property, and by reducing IRI-related
lipid peroxidation markers [21]. Moreover, unlike
glutamate receptor antagonists, pregabalin exhibits an
excellent safety profile by suppressing Ca++ entry into
presynaptic terminals and thereby reducing the release of
not only glutamate but also other excitotoxic substances
such as noradrenaline; thus, it shows more activity on the
progressive cascade. Pregabalin also exhibits a mechanism
to overcome various hazards caused by NMDA receptor
antagonists [20].
Few studies have shown that pregabalin has protective
effects against IRI, and these studies have been conducted
only on animals. Asci et al. revealed that pregabalin
reduced the level of lipid peroxidation markers, such as
thiobarbituric acid reactive substances (TBARS), during
cerebral ischemia-reperfusion, and instead increased the
activity of glutathione peroxidase (SGH-PX) and CAT
enzymes, which are the most important antioxidant
enzymes against reactive oxygen substrates [8]. Here,
pregabalin had no effect on IMA but prevented the
reduction in CAT activity during the reperfusion period.

KARACA et al. / Turk J Med Sci
Ozer et al. investigated the effects of different doses of
pregabalin on lower limb IRI and erythrocyte deformity.
Although there was no difference between the doses,
they did not observe any negative effects on erythrocyte
deformity in the pregabalin groups [22]. Ozturk et al.
studied the effect of different doses of pregabalin (50 mg
and 200 mg) on muscular ischemia-reperfusion and found
that interstitial inflammation and IMA levels increased
in the ischemia-reperfusion group; although the former
was reduced in the pregabalin group, the drug exerted no
effect on the IMA level. Additionally, the authors were of
the opinion that the administration of pregabalin at high
doses has a protective effect [4]. In our study, the effect of
pregabalin on the level of IMA, which is produced after
malondialdehyde’s interaction with plasma lipoprotein, a
lipid peroxidation product, was not observed.
The antioxidant system, which is the sum of different
antioxidant products containing enzymes, nonenzymatic
antioxidants, and an array of small molecules, can reduce
the extent of ROS- and free radical-induced oxidative
damage. These known and unknown antioxidant products
form the complex antioxidant system of the human body
[6]. Because TAS is a marker reflecting all antioxidant
levels [23], we considered the effect on TAS value in the
reperfusion period as our primary outcome. Excessive
depletion of oxidants and/or antioxidants leads to the
development of oxidative stress in an organism [24]. ROS
produced as a result of tourniquet application-induced IRI,
as well as the products formed by a series of reactions, lead
to the generation of oxidative stress in an organism. Owing
to these products, the injury not only causes local tissue
damage but also distant organ damage [1]. CAT is one
of the most important antioxidant enzymes against ROS
[8]. In numerous studies, IMA levels increased in cases of

acute ischemia such as that of the skeletal muscles as well as
cerebral, myocardial, and pulmonary infarction/ischemia
[25]. TOS is a marker reflecting the combined activity
levels of all oxidants [26]. Our study is the first to investigate
the protective effect of pregabalin against acute muscular
IRI by demonstrating the ability of the drug to inhibit the
presynaptic release of NMDA receptor-bound glutamate.
In our study, no difference was noted in the reperfusion
period between Groups P and C according to the primary
outcome. In contrast, we demonstrated that pregabalin
reduced IRI marker levels by decreasing the TOS level;
however, it increased protective factors against IRI by
increasing the TAS level while maintaining the CAT level.
We suggest that pregabalin is ineffective against IRI, but it
contributes to the body’s antioxidant system.
This study has a few limiting factors. First, ischemiareperfusion marker levels were not analyzed in tissues.
Second, glutamate levels were not measured at the
preischemic time point as well as at ischemic and
reperfusion time points. Third, the actual beneficial effects
on long-term variables, such as mobility of the operated
knee or the first walking time during the postoperative
period, were not assessed. Finally, we did not evaluate
infection marker levels and immune functions.
In conclusion, two-time preoperative administration
of 150 mg of pregabalin does not result in complete
antioxidative activity. However, pregabalin contributes to
the human body’s antioxidant system against oxidative
stress generated by tourniquet-induced IRI occurring
during total knee arthroplasty under combined spinal
epidural anesthesia.
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